A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

Inclusion Criteria: 1. Female subjects aged 18 to 75 years old； 2. ECOG performance status 0-1; 3. Life expectancy is not less than 12 weeks; 4. Histological or cytological confirmation of ER+/HER2- recurrent/metastatic breast cancer; 5. Participants with measurable disease must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST1.1; 6. Adequate function of major organs; 7. Voluntary participation in the study, signed informed consent, good compliance and willingness to cooperate with follow-up. Exclusion Criteria: 1. Confirmed diagnosis of HER2 positive disease; 2. Participants who previously received SHR6390 or VEGFR inhibitors; 3. Allergy to study drug or its components; 4. Participated in other drug clinical trials within 4 weeks before the first dose; 5. Other malignancies within 3 years, except cured non-melanoma skin cancer , skin basal cell carcinoma and squamous-cell carcinoma or carcinoma in situ of the cervix; 6. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \> 2), or ventricular arrhythmia which need medical intervention； 7. Tumor has invaded important blood vessels or the tumor is likely to invade important blood vessels and cause fatal hemorrhage during treatment; 8. Urine routine test indicates urine protein ≥(++), or 24-hour urine protein \>1.0g; 9. Active HBV/HCV/HIV infection; 10. The investigators determined that other conditions were inappropriate for participation in this clinical trial； 11. Pregnant or breast-feeding women; 12. Central nervous system (CNS) invasion.